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Adaptive immune responses to Candida
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Fungal infections are becoming increasingly prevalent in
the human population and contribute to morbidity and
mortality in healthy and immunocompromised individuals
respectively. Candida albicans is the most commonly
encountered fungal pathogen of humans, and is frequently
found on the mucosal surfaces of the body. Host defense
against C. albicans is dependent upon a ﬁnely tuned
implementation of innate and adaptive immune responses,
enabling the host to neutralise the invading fungus. Central
to this protection are the adaptive Th1 and Th17 cellular
responses, which are considered paramount to successful
immune defense against C. albicans infections, and enable
tissue homeostasis to be maintained in the presence of
colonising fungi. This review will highlight the recent
advances in our understanding of adaptive immunity to
Candida albicans infections.
Introduction
The human body is a complex environment which is colon-
ised both internally and externally by a huge number of different
microbial species including bacteria, fungi and viruses. The
maintenance of tissue homeostasis in the face of such overwhelm-
ing microbial diversity is critical to health and is dependent upon
effective immune surveillance. Candida albicans is a polymorphic
fungus found in the digestive tract and on other mucosal surfaces
of the body (e.g. oral cavity and vagina). The fungus is considered
to be a normal constituent of the microflora in »50% of the
human population1 and is the cause of superficial mucosal infec-
tions such as oral and vaginal thrush which can occur following
perturbations in the localized mucosal environment. C. albicans
is also capable of causing life threatening illness and accounts for
significant rates of mortality (40%) in the immunocompromised
and those receiving immunosuppressive therapies.2 The dichot-
omy between harmless carriage and the onset of potentially life
threatening infection stems from 2 critically important factors,
namely the presence or absence of an effective immune response
and the ability of the fungus to alter its morphology.
C. albicans can grow in a number of distinct physical forms
including unicellular yeast, pseudohyphae and hyphae.1 The
morphological transition(s) which occur during growth are
reversible,3-5 and such physical plasticity is believed to facilitate
pathogenicity. Growth of C. albicans as unicellular yeast is typi-
cally associated with harmless colonisation (commensalism)
whereas pseudohyphal and hyphal growth is more closely associ-
ated with infection. However, it is important to emphasize that
this mutually exclusive view of morphology during health or dis-
ease is somewhat oversimplified, and may not accurately reflect
the true situation during clinical pathogenesis where multiple
morphologies are often encountered simultaneously. While infec-
tions of the mucosal surfaces are predominantly associated with
the hyphal form of the fungus, widespread dissemination
throughout the body is facilitated by the yeast morphology where
cells bud-off from pre-established hyphae and transit to remote
tissues and organs such as the kidneys.
A complex and dynamic relationship exists between C. albicans
and the human host, the balance of which is influenced greatly by
the immune system. Indeed, the pathogenic potential of C. albi-
cans is primarily determined by the effectiveness of the host
immune response. A state of relative co-existence is maintained
between host and fungus in healthy individuals, whereby growth
is restricted to the harmless commensal form. However, the mor-
phological restrictions imposed upon fungal growth during health
are removed in the absence of effective immune surveillance,
which allow fungal burdens to increase as growth continues
unchecked. The hyphae of C. albicans can breach mucosal surfaces
causing infection. Hyphal growth causes damage to the underlying
tissue and if it progresses to the point where access to the host vas-
culature is enabled, the fungus can disseminate throughout the
body. Furthermore, many fungal infections also result from the
use of indwelling medical devices including intravenous lines,
catheters and drains, which bypass the physical barrier provided
by the mucosal surface, facilitating access to the bloodstream.
Such deep-seated systemic infections are a significant threat to life,
and patients suffering fromHIV/AIDS and those receiving immu-
nosuppressive therapy are particularly susceptible.
Defense against microbial infection is provided by an exquisite
interplay between the innate and adaptive arms of the host
immune system which function together to eliminate pathogens
from the body. In this review we will summarise the basic features
of the adaptive immune response to C. albicans infection,
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describing recent advances in our understanding of adaptive
immunity to this medically important fungus.
Host Recognition of Candida albicans:
Dendritic Cells
Dendritic cells (DCs) are specialized antigen presenting cells
(APCs) that play a central role in immune defense against patho-
gens, serving as a critical conduit between the innate and adaptive
immune responses. DCs are vital for the initiation of adaptive T-
cell-mediated immune protection against C. albicans. Immature
DCs patrol the peripheral tissues beneath mucosal surfaces and are
recruited to the site of infection in response to chemokines and
antimicrobial peptides (e.g., CCL206-8 and b-defensin 29,10
respectively), secreted by epithelial cells in response to microbial
infection. Once recruited, recognition of C. albicans by DCs
occurs through interactions between pattern recognition receptors
(PRRs) expressed on the surface of the DC and pathogen-associ-
ated molecular patterns (PAMPs) present on the fungal cell wall.11
PRRs including C-type lectin receptors (CLRs)12 such as dec-
tin-1, dectin-2 and dendritic cell-specific intercellular adhesion
molecule-3-grabbing non-integrin (DC-SIGN), mannose recep-
tor (MR), Mincle, Galectin-3, toll-like receptors (TLRs)13 (such
as TLR2 and TLR4), and complement receptor 3 (CR3) have all
been associated with recognition of fungi. PRRs involved in fun-
gal detection recognize conserved structural motifs present as
part of the fungal cell wall, such as N-linked14 and O-linked
mannans and b-glucans.15 Although this initial interaction
between host and fungus is driven primarily through innate
rather than adaptive recognition, it is nevertheless a crucial event
required for the initiation of an adaptive immune response. Once
detected, the fungal cells are phagocytosed by DCs and
degraded,16 providing a source of exogenous protein which is
processed into antigenic peptides within acidified vesicles. These
fungal peptide antigens are assembled onto class II molecules of
the major histocompatibility complex (MHC II) and subse-
quently transported to the surface of the activated DC. Acquired
fungal antigens are presented to memory T-cells present in the
local environment, and this process is accompanied by the migra-
tion of the DCs to the draining lymph nodes, where the antigens
are presented to naive T-lymphocytes.
Interestingly, the activation of DCs during C. albicans infec-
tion results in different antigen-specific immune responses. Pre-
sentation of C. albicans antigens by Langerhans cells is required
to elicit Th17 responses but does not promote the development
of CD8C cytotoxic T-lymphocyte (CTL) responses.17 In con-
trast, LangerinC dermal DCs stimulate both Th1 and CTL
responses while simultaneously inhibiting the development of
the Th17 response. Induction of a CTL response indicates that
antigens derived from phagocytosis of fungal cells were cross-pre-
sented through the MHC I pathway for display to CD8C T-lym-
phocytes. Thus, mixed populations of DCs have non-redundant
functionality and can drive CD4C and CD8C T-cell responses
against C. albicans.
T-lymphocytes sample the antigen presented to them using T-
cell receptors (TCRs) expressed on their surface. Specificity to a
potentially unlimited number of antigenic molecules is enabled
by random variations in the amino acid sequence (and hence
structure) of the antigen binding region of the TCR. Binding of
the TCR to either MHC I or MHC II molecules displaying proc-
essed fungal antigen is facilitated by the expression of the co-
receptors CD8C and CD4C respectively, and authenticated
though interactions between CD28 expressed on the T-cell and
CD80/CD86 on the APC. Recognition of antigen is accompa-
nied by the secretion of cytokines which drive the activation and
differentiation of the naive T-lymphocyte into one of a number
of different possible T-helper (Th) subsets.
Signaling Events in DCs that Drive Th Subset
Differentiation
The recognition of PAMPs by PRRs results in the activation
of signaling pathways within the DC which ultimately results in
the induction of a specific adaptive cellular immune response.
The signaling events that transpire following fungal recognition
by the DC and the induction of cellular immunity are both
dynamic and complex, and have yet to be characterized in full.
The CLR dectin-1 is expressed on the surface of APCs and
plays a central role in the orchestration of responses to C. albi-
cans. Dectin-1 is comprised of an extracellular carbohydrate rec-
ognition domain and a partial immunoreceptor tyrosine-based
activation (ITAM) motif and is the receptor for fungal cell wall
b-glucan.18 The recognition of fungal b-glucan by dectin-1 trig-
gers receptor activation through phosphorylation of the cyto-
plasmic domain19,20 which in turn leads to recruitment and
activation of the spleen tyrosine kinase (SYK)21 (Fig. 1A ). Asso-
ciation of phosphorylated dectin-1 with Syk triggers the assembly
of the caspase recruitment domain (CARD) complex consisting
of CARD9, Bcl-10 and MALT1.19,20,22 The importance of this
process in adaptive immune responses to C. albicans can be dem-
onstrated as CARD9¡/¡ mice are unable to mount Th17
responses to oral infection.23
Assembly of the CARD complex leads to activation of the IkB
kinase complex which promotes activation and nuclear transloca-
tion of the transcription factor NF-kB22 (Fig. 1 B). Gene tran-
scription mediated via NF-kB signaling results in secretion of
pro-inflammatory cytokines and the concomitant upregulation
of co-stimulatory molecules on the APC surface (Fig. 1 D), the
net effect being the induction and differentiation of naive T-cells
into distinct Th lineages (Th1, Th2, Th17, Treg). In addition to
the “classical” signaling mediated through Syk and p65, dectin-1
can also signal through the non-cannonical NF-kB subunit RelB
and importantly, through a second, Syk-independent pathway
dependent upon Raf-124. All these pathways converge on NF-kB
to drive Th1 and Th17 polarization, and subsequent adaptive
immunity against C. albicans.24
Other CLRs have also been reported as playing a role in driv-
ing adaptive immune responses to C. albicans, including dectin-
2.25 However in contrast to dectin-1 which, during canonical
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signaling, interacts with Syk directly,
dectin-2 induces signaling through
Syk indirectly by association with the
FcRg chain.26 Blockade of dectin-2
expressed on DCs has been reported
to reduce Th17 responses during sys-
temic infection with C. albicans.25
T-cell Responses to Candida
albicans
T-lymphocytes (T-cells) are an
integral component of the host adap-
tive immune response to C. albicans
infection and provide direct and
indirect means of controlling fungal
proliferation. Both CD4C (T helper
cells) and CD8C (CTL) T-cells have
been shown to play a role in anti-fun-
gal immunity, and their activation is
controlled by dendritic cell popula-
tions. Although CTLs have been
shown to inhibit the growth of C.
albicans hyphae in vitro,27 the princi-
pal mechanism of adaptive immune
priming employed by DCs occurs
through the presentation of fungal
antigen to naive CD4C T-cells, gen-
erating a T-helper (Th) response.
The CD4C Th cell response is the
predominant cell-mediated adaptive
immune response to C. albicans
infection at mucosal surfaces. Unlike
CTLs, CD4C T-cells do not possess
direct cytolytic activity but neverthe-
less play a crucial role in the cellular
adaptive response to fungal infection.
The importance of the Th cellular
response in driving protective immu-
nity against C. albicans is highlighted
by the prevalence of oropharangeal
candidiasis (OPC) in HIVC/AIDS
patients where the CD4C T-cell
count is depleted.28,29 Indeed, the
correlation between HIV/AIDS and
C. albicans infection in the oral cavity
is now such that the presence of OPC
is now widely regarded as a reliable
predictor of low CD4C cell
count.28,29
There are 4 different Th subsets (Th1, Th2, Th17 and Treg),
and the development of each specific subset is dictated by the
cytokines and microenvironment present at the instance of naive
CD4C T-cell priming by DCs. The cytokines that drive the dif-
ferentiation of each particular Th phenotype are inhibitory to the
development of the others, thereby maximising the potential that
only one type of Th response is initiated at any one time. This so
called “polarization” of Th differentiation has a profound impact
on the outcome of the adaptive response and is heavily dependent
upon the prevailing cytokine milieu. Th1 responses were
Figure 1. Overview of adaptive T-cell responses to Candida albicans infection. A fungal PAMP (b-glucan)
engages with the PRR dectin-1 (A), stimulating receptor phosphorylation and recruitment of the spleen
tyrosine kinase (SYK). The association of dectin-1 with SYK activates assembly of the CARD complex
(CARD9, BCL-10 and MALT-1), which stimulates nuclear translocation of the transcription factor NF-kB (B).
The NF-kB transcription factor drives the expression of pro-inﬂammatory cytokines and co-stimulatory
molecules required during antigen presentation. As well as signaling and gene transcription, activation of
dectin-1 and recruitment of SYK triggers phagocytosis of C. albicans (C). The phagocytosed fungus is
degraded in the phagocytic compartment and fungal antigens are loaded onto MHC II molecules for pre-
sentation to naive CD4C T-cells. Recognition of antigen by a T-cell receptor (TCR) in the presence of co-
stimulation from CD28 and CD80/86 (D) is followed by cytokine-directed polarization to one of the 4
known Th subsets (E). Th1 and Th17 cellular responses confer immune protection, whereas Th2 responses
are considered refractory to fungal clearance.
www.tandfonline.com 329Virulence
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 01
:37
 22
 Ja
nu
ary
 20
16
 
historically regarded as being the predominant defensive cellular
response to C. albicans, resulting in fungal clearance from the
oral cavity and gastrointestinal tract. However, this view of the
importance and effective contribution of the Th1 phenotype to
protection against C. albicans infection at mucosal surfaces has
since been superseded by the Th17 response. In contrast to the
protective Th17/Th1 phenotypes, induction of a Th2 phenotype
is more closely associated with increased growth and dissemina-
tion of the fungus.
DCs that phagocytose C. albicans yeast cells are stimulated to
produce interleukin-12 (IL-12), which drives polarization to the
Th1 subset. Upon stimulation with IL-12, Th1 cells initiate
autocrine signaling via secretion of interferon-gamma (IFN-g)
which serves to upregulate the expression of the IL-12Rb2 recep-
tor rendering the cells increasingly sensitive to IL-12 stimulation,
thereby perpetuating differentiation to the Th1 phenotype.30 In
contrast, polarization to the Th2 phenotype is driven by IL-4
and is accompanied by further secretion of IL-4.
IL-17 secreting T-lymphocytes (Th17 cells) are an additional
subset of Th cell which express the chemokine receptors CCR4
and CCR6 on their surface31 and are developmentally distinct
from the Th1 and Th2 lineages.32 Th17 cells secrete numerous
cytokines including IL-17A, IL-17F and IL-22 and are critically
important for immune protection against C. albicans at the
majority of mucosal sites in the body. Indeed, such is the involve-
ment of Th17 cells in the immune response to oral and dermal
candidiasis they are now regarded as the predominant cell type
that confer protection against C. albicans at these locations.33,34
Interestingly, IL-17 and IL-22 do not contribute to immune pro-
tection in vaginal mucosa,35 highlighting the subtle differences in
immune response requirements at different mucosal sites.33,34
IL-17 plays a key role in recruiting and activating neutrophils,36
while IL-22 enhances epithelial barrier function.37 Differentiation
of naive CD4C T-cells to the Th17 phenotype is driven initially
by IL-1b,38,39 while maturation and terminal differentiation is
dependent upon IL-23 signaling.40 Th17 differentiation is further
influenced by IL-6, which has been shown to be produced by epi-
thelial cells in response to C. albicans infection.41 Notably, the
production of both IL-6 and IL-23 from antigen presenting cells
results from recognition of C. albicans mannan.42
More recently, an additional class of natural Th17 (nTh17)
cells have been described that are phenotypically distinct from
conventional CD4C Th17 cells.43-45 nTh17 cells function as
innate sentinels in the oral mucosa and together with gd T cells,
secrete IL-17 in response to C. albicans.45 Notably, gd T cells
produce large quantities of IL-17,45 yet again highlighting the
close relationship between innate recognition of C. albicans and
downstream adaptive immune responses. It is also important
when considering immune responses to C. albicans to be aware
that many of the cytokines now thought to be important in these
responses (e.g. IL-17A, IL-22) can also be produced by innate
lymphoid cells (ILCs) such as the aforementioned nTh17 cells,
gd T cells, as well as ILC3 cells. Further, many of the in vivo
models of mucosal C. albicans infection are skewed toward assay-
ing innate rather than adaptive immune responses given the time-
scales over which these models are carried out.
The importance of the Th17 phenotype cytokines in anti-
Candida responses is most vividly portrayed by data from both
knockout mice and human patients. Mice unable to produce IL-
23 are highly susceptible to OPC,46 while mice lacking IL-17
receptor-A (IL-17RA¡/-) or IL-23p19 (IL-23p19¡/-) have
increased susceptibility to both OPC and systemic candidia-
sis.36,47 Moreover, IL-17RC¡/- mice (deficient in the second IL-
17 receptor chain) are also susceptible to OPC.48 Both IL-17 and
IL-23 are essential in preventing fungal skin infections33 and
Th17 cells secrete IL-22 which limits fungal growth.37
In addition to acquired disorders of CD4C T-cell immunity
that predispose to C. albicans infection (HIV/AIDS), the critical
nature of the protection provided by IL-17/Th17 cells is further
emphasized when one considers the impact of inherited genetic
mutations which affect the efficacy of IL-17/Th17 responses in
otherwise healthy individuals.
Patients with inherited disorders in Th17-mediated anti-fun-
gal immunity frequently present with chronic mucocutaneous
candidiasis (CMC), which manifests as severe infection of the
nails, skin and upper gastrointestinal tract. IL-12 and IL-23 are
important cytokines for the development of Th1 and Th17
responses respectively. The human IL12RB1 gene encodes for an
integral component of the receptor to IL-12 and IL-23, and
approximately 25% of patients deficient in IL-12Rb1 are prone
to CMC.49,50 In patients with autosomal dominant Hyper-IgE
syndrome, the differentiation, development and number of circu-
lating Th17 cells is significantly reduced51-53 due to mutations in
Signal Transducer and Activator of Transcription 3 (STAT3),
and CMC is a key phenotype in these individuals.54,55 Further,
Th17 development and associated anti-fungal activity is also
impaired by gain-of-function mutations in STAT1.56
A marked reduction in the number of IL-17 secreting T-cells is
observed in patients carrying the dominant-negative autosomal
recessive Q258X mutation in caspase recruiting domain-contain-
ing protein 9 (CARD9)57 and this mutation has been associated
with increased susceptibility to fungal infection.58 Furthermore,
individuals with autosomal recessive autoimmune polyendocrin-
opathy syndrome 1 (APS-1), caused by mutations in the gene
encoding the human autoimmune regulator protein (AIRE)59,60
produce neutralising antibodies against IL-17A, IL-17F and IL-
22. The continual depletion of these key Th17 cytokines results in
an associated CMC.61,62 Importantly, the susceptibility of APS-1
patients to opportunistic pathogens is seemingly restricted to C.
albicans alone, highlighting the specific and essential contribution
of IL-17 to anti-C. albicans immunity. Moreover, both an autoso-
mal recessive mutation of glutamine 284 to a premature termina-
tion codon in the receptor for IL-17A (IL-17 RA) and an
autosomal dominant mutation (S65L) in IL-17F also predispose
individuals to CMC.63 A T536I mis-sense mutation in ACT1 (an
adaptor protein involved in IL-17 signaling) is reported to reduce
activity and impaired IL-17A and IL-17F-mediated immunity.
Patients harbouring the ACT1 mutation have T-cells which are
unresponsive to IL-17E and an increased prevalence of CMC.64
One of the classical hallmarks of adaptive immunity is the
establishment of permanent immunological memory against a
specific antigen, which can be brought to bear against a pathogen
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in the face of a secondary immune challenge. Long-term adaptive
immunity against C. albicans has been observed in mice chal-
lenged and then re-challenged with the fungus. In this system, a
stable and robust antigen-specific adaptive Th17 immune
response against C. albicans was reported,34 but the establishment
of bona fide immunological memory remains to be fully demon-
strated. Taken collectively, these studies clearly demonstrate the
essential role that Th17 cells, their associated cytokines and by
extension, adaptive immunity, play in combating C. albicans
infections.
Antibody Responses to Candida albicans
Endogenous antibody responses to C. albicans infection in
humans are regarded as playing a relatively minor role in immune
protection against the fungus, and are widely considered to be
significantly less effective than cellular (Th17/Th1) responses.
Due to their accessibility, molecules displayed on the cell surface
of C. albicans provide ideal targets for antibody-mediated
immune protection. Mannoproteins with complex O- and N-
linked mannose polysaccharides are an integral component of the
C. albicans cell wall65 and are a major target for anti-Candida
antibodies. The binding of antibodies to exposed cell surface
components of the infecting fungus may serve to hinder or pre-
vent biological function. Indeed, monoclonal antibodies gener-
ated against mannoprotein interfere with fungal adhesion to host
substrates and germ tube formation,66 while patient-derived anti-
bodies against a 58 kDa cell surface mannoprotein of the fungus
prolonged survival following systemic infection in mice.67
Antibodies generated in mice against the surface mannan of
C. albicans can confer varying degrees of protection, depending
upon whether the subsequent fungal infection is mucosal or sys-
temic.68 Vaccination with C. albicans mannan rendered mice less
susceptible to disseminated candidiasis and polyclonal serum
from vaccinated animals conferred protection to both naive mice
and those with severe combined immune-deficiency (SCID).69
Administration of a recombinant human monoclonal antibody
against C. albicans mannan to mice enabled prolonged survival
following an otherwise lethal inoculum of the fungus.70
The agglutinin-like sequence proteins of C. albicans also reside
at the cell surface, and monoclonal antibodies which bind to
Als3p interfere with adhesion to epithelial surfaces, filamentation,
acquisition of iron, and also possess fungicidal activity.71,72 Inter-
estingly, antibody-mediated protection against C. albicans is not
restricted to cell surface molecules alone. Antibody-mediated
inhibition of secreted aspartyl proteinase (SAP) activity was
reported to bestow increased protection against vaginal infection
in rats,73 while human antibodies specific for C. albicans heat
shock protein 90 (Hsp90) protected against systemic candidiasis
in mice.74
Despite these observations, there is the paradox that B-cell
deficiency in mice does not cause increased susceptibility to C.
albicans infection,75-77 highlighting the lack of robust antibody-
mediated protection and emphasizing the predominance of adap-
tive cellular responses.
Given the extremely modest levels of protection conferred by
antibodies in response to C. albicans infection, it could be argued
that the inherent immunogenicity of C. albicans antigens is lim-
ited in their natural context when presented to B-cells. However,
it is also clear that purified antigens, when presented to the
immune system in conjunction with a suitable carrier protein
and adjuvant are capable of eliciting the production of antigen-
specific antibodies that can confer some, albeit limited, protec-
tion (see Vaccines to Candida albicans).
Subversion of adaptive immune responses by Candida
albicans
As with most pathogens, C. albicans has developed mecha-
nisms for avoiding immune responses. This can include eva-
sion of recognition events or even subversion of normal
immune responses. The mechanisms by which C. albicans
manages this are varied. For example, the cellular immune
response driven during infection can be influenced by fungal
morphology. Monocytes that phagocytose C. albicans yeast
cells or germ tubes were unable to differentiate into DCs,
and internalisation of germ tubes was reported to render cells
incapable of inducing Th polarization.78 Further, the yeast
and hyphal forms of C. albicans exert opposing effects on
DCs, skewing Th polarization induced both in vitro and in
vivo.79,80 Such a polarization of the cytokine response may
function to subvert Th subset differentiation to those which
enable fungal persistence within the host. DCs which phago-
cytose C. albicans yeast cells or those pulsed with yeast cell
RNA promote development of Th1 responses, leading to fun-
gal clearance, whereas DCs that internalise hyphae or those
which receive hyphal RNA generate Th2 responses leading to
fungal perpetuation.79,80 Importantly, DCs pulsed ex vivo
with yeast but not hyphae were reported to confer anti-fungal
protection when adoptively transferred into mice.79 In addi-
tion to morphological influences, C. albicans can secrete a
soluble factor which reduces IL-17 production from human
peripheral blood mononuclear cells in vitro,81 suggesting that
the fungus may have the potential to dampen host Th17
responses. Furthermore, it has also been suggested that the
presence of IL-17A may facilitate fungal adaptation to the
host environment.82
T-regulatory (Treg) cells are known to play a central role in
the regulation of cellular immune responses to microbial infec-
tion. The induction of disseminated candidiasis in mice was
reported to drive the expansion of a population of splenic
Foxp3C Treg cells resulting in the exacerbation of disease pathol-
ogy. Interestingly, subsets of Foxp3C Treg cells were observed to
induce Th17 responses, albeit to the detriment of the host.83 In
contrast to these findings is the observation that Treg cells con-
sume IL-2 (thereby preventing IL-2-mediated inhibition of
Th17 polarization), assisting the generation of protective Th17
responses mounted during murine OPC.84 Clearly, the roles(s)
played by Treg cells in response to C. albicans infection have yet
to be characterized in full.
Taken together it appears probable, whether intentional or
otherwise, that C. albicans is able to influence the outcome of the
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host immune response in some circumstances, possibly to cir-
cumvent immune clearance and facilitate persistence.
The role of the inflammasome in the adaptive immune
response to Candida albicans
The complex interplay between innate and adaptive immune
responses that enables fungal clearance is further demonstrated
by the involvement of the inflammasome in response to fungal
challenge. Inflammasomes are cytosolic multi-protein complexes
consisting of a PRR, an adaptor protein (e.g., ASC) and caspase-
1, whose assembly is triggered via innate recognition of PAMPs
by intracellular nucleotide-binding domain and leucine-rich
repeat-containing (NLR) proteins or AIM2-like receptors
(ALRs).85 It is becoming increasingly clear that these structures
play an important functional role in the adaptive immune
response to fungal infection. The end point of inflammasome
activation is the production of fully mature inflammatory cyto-
kines IL-1b and IL-18. IL-1b and IL-18 are produced as inactive
precursors that undergo caspase-mediated cleavage to yield bio-
logically active molecules. Inflammasome activity is required to
drive caspase-dependent maturation of IL-1b and IL-18, with
subsequent effects on adaptive Th1 and Th17 cellular
responses.38,86,87 Accordingly, while the initiation of inflamma-
some activity is associated with innate immunity, the production
of functionally mature IL-1b and IL-18 nevertheless influence
the outcome of the adaptive immune response.
A number of different inflammasomes are known to be
involved in the response to C. albicans infection. By far the best
characterized of these is the NLRP3 inflammasome which con-
sists of Nlrp3 complexed with apoptosis-associated speck-like
protein with caspase recruitment domain (ASC) and caspase-1.
The ability to produce mature IL-1b and IL-18 through the
NLRP3 inflammasome is crucial for adaptive cellular protection
against C. albicans. Activation of the NLRP3 inflammasome is
triggered by C. albicans hyphae,88 and has an impact in signaling
through other PRRs involved in anti-Candida immunity. For
example, NLRP3/ASC caspase-1 activity is a critical factor in
SYK/CARD9 signaling induced by TLR2 and dectin-1.89,90 Fur-
ther, secretion of IL-1b from DCs stimulated with fungal b-glu-
can required NLRP3 inflammasome activity and cells deficient in
either Nlrp3 or ASC were impaired in their ability to secrete IL-
1b.91 The importance of the NLRP3 inflammasome in anti-Can-
dida responses can be seen in studies using knock-out mice. Mice
lacking in either TLR2, dectin-1, caspase-1 or Nlrp3 are highly
susceptible to systemic C. albicans infection,88-90 while mice
unable to produce caspase-1 or ASC were more susceptible to
disseminated candidiasis and exhibited reduced Th1/Th17 reac-
tivity concomitant with increased fungal burden in the kidneys.92
These inflammasome effects are important for more than cell-
mediated immunity, with studies showing that NLRP3 activity
was required for the generation of antigen-specific antibody
mediated immune protection against C. albicans in vivo.91 In
addition to NLRP3-mediated protection, immune defense
against C. albicans infection can also be orchestrated through the
NLRC4 inflammasome which functions to regulate resistance to
infection in the oral cavity and limits early systemic dissemina-
tion following oral infection in vivo.93
NLRP10 is another member of the NLR family which con-
tributes to adaptive immune protection against disseminated can-
didiasis in vivo94 and is expressed on DCs and CD4C, but not
CD8C T-cells. Mice lacking NLRP10 exhibited impaired Th1
and Th17 responses to C. albicans infection concomitant with an
increased presence of both yeast and hyphae in the renal cortex
and medulla.94 Importantly, while adaptive cellular responses
were negatively affected by the absence of NLRP10, activation of
the NLRP3 inflammasome and secretion of IL-1b were not
affected, indicating that while both NLRP3 and NLRP10 con-
tribute to adaptive protection against C. albicans infection, they
do so by different pathways.94 As can be seen, the exact role of
inflammasome activation in adaptive immune responses is diffi-
cult to isolate, given the parallel role these complexes play in
innate immunity. The reality is likely to be a multifaceted inter-
play between the different inflammasome complexes and fungal
PAMPs, resulting in complementary activation of both innate
and adaptive immunity. It should be noted that the cytokine
cocktail produced by inflammasome activity (IL-1b and IL-18)
will help drive the development of a Th17 phenotype in na€ıve T-
cells, thus the innate immune activation of inflammasomes can
still have an impact on adaptive immune responses.
Since NLRs are intracellular receptors, the activation of
inflammasome assembly typically proceeds following phagocyto-
sis/internalisation of the infecting fungus. However, recognition
of C. albicans by DCs expressing the extracellular PRR dectin-1
can also trigger the assembly of a non-canonical inflammasome
complex consisting of CARD9, Bcl-10, MALT1, ASC and cas-
pase-8, rather than caspase-195. Assembly of this multi-protein
complex enables processing of inactive IL-1b to the active form
in a caspase-8 dependent manner. Intriguingly, while activation
of the NLRP3/caspase-1 inflammasome by C. albicans is depen-
dent upon internalisation of the fungus, blocking the internalisa-
tion of C. albicans does not affect caspase-8-dependent
maturation of IL-1b from the non-canonical inflammasome
complex.95 Hence, induction of protective Th17-based immu-
nity against C. albicans can be triggered following intracellular
and extracellular recognition of the fungus in a manner depen-
dent upon the activity of classical and non-canonical inflamma-
somes respectively.
Compartmentalisation of Immunity
C. albicans is known to infect multiple mucosal sites including
the oral and vaginal cavities in particular. Each of these surfaces
has their own immune mechanisms and susceptibilities to infec-
tion. For example, while oral thrush is generally associated with
significant underlying changes, such as denture use or immune
deficiencies (AIDS, transplantation therapy, cancer treatments),
vulvovaginal candidiasis (VVC) is a much more common occur-
rence in the general population. Indeed, »75% of women of fer-
tile age will experience at least one incidence of VVC96,97 and it
has been estimated that 5–10% of women will suffer from
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repeated or chronic episodes of VVC.98,99 It is therefore highly
likely that there are differences in the immunity generated at
each of these different sites. Interestingly, adaptive Th17
responses appear to play no role in vaginal protection to C. albi-
cans, with no change in the vaginal fungal burden of IL-
23p19¡/-, IL-17RA¡/- and IL-22¡/- mice compared with wild
type controls.100 This highlights the fact that although there are
common anti-fungal mucosal immune responses, it is also highly
likely that there is a varying degree of specificity for each of these
mucosal surfaces to the fungus. In particular, it is noteworthy
that responses to systemic infection differ from responses at
mucosal surfaces. Systemic responses for example, are still
regarded as being predominantly Th1, while mucosal responses
are now known to be predominantly Th17 in nature.
The contribution of adaptive immune responses againstC. albi-
cans during vaginal infection remains somewhat unclear. Despite
participating in adaptive immune protection at a number of differ-
ent sites in the body,101-103 Th1 cells play no significant role in
protection against C. albicans in the vaginal environment,104 and a
precise biological role for this so called “compartmentalisation of
immunity” has yet to be unequivocally established.
In an experimental model of VVC, DCs were detected in the
draining lymph nodes of the surrounding vaginal tissue. However,
the predominant subset of DC found within the nodes were plas-
macytoid dendritic cells (pDCs),105 which are associated with
immunological tolerance and poor induction of T-cell prolifera-
tion,106 rather than myeloid DCs which promote inflammatory
responses and fungal clearance. Importantly, the pDCs were
detected prior to, and throughout the entire course of infection
and did not upregulate expression of MHC II, CD80 or CD86,105
consistent with a localized, tissue-specific tolerance to the fungus.
The involvement of Th17 responses to C. albicans infection in
the vagina have yet to be fully elucidated. Induction of VVC in
mice stimulated the production of both IL-17 and IL-23,
together with a potent influx of neutrophils.107 However, despite
the role played by IL-17/Th17 in driving neutrophil recruitment
to the sites of infection, the presence of neutrophils was ineffec-
tual and the severity of infection was not diminished.107 Interest-
ingly, the secretion of IL-17 was noted to influence the
production of the anti-microbial peptides b-defensin 2 and
b-defensin 3. Reducing the level of IL-17 exacerbated VVC
severity while simultaneously reducing the level of b-defensin 2,
whereas production of b-defensin 2 was increased following
addition of recombinant IL-17.107
In contrast to the above study, recruitment of neutrophils dur-
ing vaginal infection was observed in response to the presence of
S100A8 and S100A9 alarmins,35 and no role for the involvement
of either IL-17 or the Th17 pathway was demonstrated.100 Given
the involvement of the S100 alarmins and b-defensins, defense
against C. albicans in the vaginal environment thus appears to
be mediated through innate rather than adaptive means in
murine models of VVC. Indeed, the PRRs TLR4 and SIGNR1
have been implicated in S100 alarmin signaling in vitro, although
the situation appears to be more complex in vivo.108 Importantly,
and in keeping with the observations made above, the symptoms
caused by intravaginal challenge with live, unattenuated C.
albicans in human subjects was attributed to potent innate rather
than adaptive responses.109
Vaccines to Candida Albicans
Much attention is now being given to the development of vac-
cines to establish long-lived immunological memory against C.
albicans such that a robust and targeted adaptive immune
response can be rapidly invoked upon secondary fungal chal-
lenge. The proteins selected for inclusion into anti C. albicans
vaccines are predominantly (but not exclusively) those factors
considered to be a requirement for virulence. One such class of
molecules are the agglutinin-like sequence (Als) adhesins, which
are required for the attachment of C. albicans to host surfaces
during infection.110,111
By far the most well studied candidate for an anti C. albicans
vaccine is Als3p (amino acids 17–432, referred to as NDV-3).
Subcutaneous injection of NDV-3 in the presence of an adjuvant
stimulated adaptive Th1/Th17 immune protection against C.
albicans bloodstream infection in mice, resulting in the recruit-
ment of activated phagocytes which facilitated fungal clearance
from infected tissues.112 Consistent with the differences in
immune responses at different mucosal surfaces, vaccination of
mice with NDV-3 results in the production of anti-Als3p IgG
and IgA antibodies and reduced fungal burdens in vaginal tissues
in a manner dependent upon both T- and B-lymphocytes, rather
than the purely cell-mediated protection seen in bloodstream
infections.113 NDV-3 was also reported as being highly effica-
cious in a mouse model of OPC ,114 has proven itself to be safe
and immunogenic in human subjects, and is now being assessed
in clinical trials.115
Mice vaccinated with an N-terminal region of Als1p are pro-
tected against a lethal innoculum of C. albicans,116 with vaccina-
tion resulting in reduced fungal burdens in tissue following
infection with C. albicans117 and other Candida species.118
Importantly, protection afforded by this vaccine is mediated via
cellular rather than humoral means, as vaccination is still success-
ful in B-cell deficient mice.116 An MHC II-bound peptide frag-
ment corresponding to a conserved region of ALS family
proteins has been isolated from DCs infected with C. albicans.119
The isolated peptide has been reported to act as a Th17 epitope
and was observed to protect mice from fatal systemic
candidiasis.119
Other families of C. albicans virulence factors have also shown
promise as potential vaccine candidates, including the secreted
aspartyl proteinases (Saps).120 Immunisation of mice with Sap2p
confers protective immunity in the face of an otherwise lethal sys-
temic challenge of C. albicans.121 Rats receiving intravaginal
immunisation with amino acids 77–400 of Sap2p were protected
against subsequent vaginal challenge with C. albicans in a manner
dependent upon the generation of anti-Sap2p IgG and IgA.122 As
well as virulence factor vaccines, other formulations have been
designed based on structural motifs. A vaccine containing the
algal b-glucan laminarin has been reported to improve immune
protection against123 both vaginal (mucosal) and systemic C.
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albicans infection in mice.123 Despite this progress, success
remains limited. No vaccines to C. albicans are clinically available
at the time of writing. However, given the prevalence of fungal
infections, particularly in the face of increasing resistance to com-
monly used anti-fungal therapies, the field of C. albicans vaccine
design will no doubt continue to flourish and remain an area of
intense study.
Concluding Remarks
Adaptive immune responses to C. albicans are crucial to
the successful eradication of infecting fungus. Despite tre-
mendous advances in our understanding of the molecular
events that underpin adaptive immunity to this opportunistic
fungal pathogen, there is still much to be discovered. It is
worth noting here that much of our understanding of the
adaptive immune responses to C. albicans is based on in vitro
studies. However, these studies have so far correlated with in
vivo findings and have provided us with a map of events in
adaptive immune responses to this medically important fun-
gal pathogen. Critically, as our understanding of the complex
relationship between innate and adaptive immunity to C.
albicans continues to evolve, and in vivo data are continually
refined, future developments will no doubt enable the provi-
sion of improved medical outcomes for those who suffer
from C. albicans infections.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
References
1. Odds FC. Candida and Candidosis. London: Bailliere
Tindall, 1988.
2. Giusiano G, Mangiaterra M, Garcia Saito V, Rojas F,
Gomez V, Diaz MC. Fluconazole and itraconazole
resistance of yeasts isolated from the bloodstream and
catheters of hospitalized pediatric patients. Chemo-
therapy 2006; 52:254-9; PMID:16899974; http://dx.
doi.org/10.1159/000094867
3. Braun BR, Johnson AD. Control of filament forma-
tion in Candida albicans by the transcriptional repres-
sor TUP1. Science 1997; 277:105-9; PMID:
9204892; http://dx.doi.org/10.1126/science.
277.5322.105
4. Braun BR, Kadosh D, Johnson AD. NRG1, a repres-
sor of filamentous growth in C.albicans, is down-regu-
lated during filament induction. EMBO J 2001;
20:4753-61; PMID:11532939; http://dx.doi.org/
10.1093/emboj/20.17.4753
5. Murad AM, Leng P, Straffon M, Wishart J, Maca-
skill S, MacCallum D, Schnell N, Talibi D, Mare-
chal D, Tekaia F, et al. NRG1 represses yeast-
hypha morphogenesis and hypha-specific gene
expression in Candida albicans. EMBO J 2001;
20:4742-52; PMID:11532938; http://dx.doi.org/
10.1093/emboj/20.17.4742
6. Thorley AJ, Goldstraw P, Young A, Tetley TD. Pri-
mary human alveolar type II epithelial cell CCL20
(macrophage inflammatory protein-3alpha)-induced
dendritic cell migration. Am J Respir Cell Mol Biol
2005; 32:262-7; PMID:15618437; http://dx.doi.org/
10.1165/rcmb.2004-0196OC
7. Sierro F, Dubois B, Coste A, Kaiserlian D, Kraehen-
buhl JP, Sirard JC. Flagellin stimulation of intestinal
epithelial cells triggers CCL20-mediated migration of
dendritic cells. Proc Natl Acad Sci U S A 2001;
98:13722-7; PMID:11717433; http://dx.doi.org/
10.1073/pnas.241308598
8. Dieu-Nosjean MC, Massacrier C, Homey B, Van-
bervliet B, Pin JJ, Vicari A, Lebecque S, Dezutter-
Dambuyant C, Schmitt D, Zlotnik A, et al. Mac-
rophage inflammatory protein 3alpha is expressed
at inflamed epithelial surfaces and is the most
potent chemokine known in attracting Langerhans
cell precursors. J Exp Med 2000; 192:705-18;
PMID:10974036; http://dx.doi.org/10.1084/jem.
192.5.705
9. Feng Z, Jiang B, Chandra J, Ghannoum M, Nel-
son S, Weinberg A. Human beta-defensins: differ-
ential activity against candidal species and
regulation by Candida albicans. J Dental Res
2005; 84:445-50; PMID:15840781; http://dx.doi.
org/10.1177/154405910508400509
10. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo
MJ, Shogan J, Anderson M, Schr€oder JM, Wang JM,
Howard OM, et al. Beta-defensins: linking innate and
adaptive immunity through dendritic and T cell
CCR6. Science 1999; 286:525-8; PMID:10521347;
http://dx.doi.org/10.1126/science.286.5439.525
11. Netea MG, Marodi L. Innate immune mechanisms
for recognition and uptake of Candida species. Trends
Immunol 2010; 31:346-53; PMID:20705510; http://
dx.doi.org/10.1016/j.it.2010.06.007
12. Hardison SE, Brown GD. C-type lectin receptors
orchestrate antifungal immunity. Nat Immunol 2012;
13:817-22; PMID:22910394; http://dx.doi.org/
10.1038/ni.2369
13. Bourgeois C, Kuchler K. Fungal pathogens-a sweet
and sour treat for toll-like receptors. Front Cell Infect
Microbiol 2012; 2:142; PMID:23189270; http://dx.
doi.org/10.3389/fcimb.2012.00142
14. Pietrella D, Bistoni G, Corbucci C, Perito S, Vec-
chiarelli A. Candida albicans mannoprotein influences
the biological function of dendritic cells. Cell Micro-
biol 2006; 8:602-12; PMID:16548886; http://dx.doi.
org/10.1111/j.1462-5822.2005.00651.x
15. BrownGD,Taylor PR, ReidDM,Willment JA,Williams
DL, Martinez-Pomares L, Wong SY, Gordon S. Dectin-1
is a major beta-glucan receptor on macrophages. J Exp
Med 2002; 196:407-12; PMID:12163569; http://dx.doi.
org/10.1084/jem.20020470
16. Newman SL, Holly A. Candida albicans is phagocy-
tosed, killed, and processed for antigen presentation
by human dendritic cells. Infect Immun 2001;
69:6813-22; PMID:11598054; http://dx.doi.org/
10.1128/IAI.69.11.6813-6822.2001
17. Igyarto BZ, Haley K, Ortner D, Bobr A, Gerami-
Nejad M, Edelson BT, Zurawski SM, Malissen B,
Zurawski G, Berman J, et al. Skin-resident murine
dendritic cell subsets promote distinct and opposing
antigen-specific T helper cell responses. Immunity
2011; 35:260-72; PMID:21782478; http://dx.doi.
org/10.1016/j.immuni.2011.06.005
18. Taylor PR, Tsoni SV, Willment JA, Dennehy KM,
Rosas M, Findon H, Haynes K, Steele C, Botto M,
Gordon S, et al. Dectin-1 is required for beta-glucan
recognition and control of fungal infection. Nat
Immunol 2007; 8:31-8; PMID:17159984; http://dx.
doi.org/10.1038/ni1408
19. Rogers NC, Slack EC, Edwards AD, Nolte MA,
Schulz O, Schweighoffer E, Williams DL, Gordon S,
Tybulewicz VL, Brown GD, et al. Syk-dependent
cytokine induction by Dectin-1 reveals a novel pattern
recognition pathway for C type lectins. Immunity
2005; 22:507-17; PMID:15845454; http://dx.doi.
org/10.1016/j.immuni.2005.03.004
20. Underhill DM, Rossnagle E, Lowell CA, Simmons
RM. Dectin-1 activates Syk tyrosine kinase in a
dynamic subset of macrophages for reactive oxygen
production. Blood 2005; 106:2543-50; PMID:
15956283; http://dx.doi.org/10.1182/blood-2005-
03-1239
21. Brown GD. Dectin-1: a signalling non-TLR pattern-
recognition receptor. Nat Rev Immunol 2006; 6:33-
43; PMID:16341139; http://dx.doi.org/10.1038/
nri1745
22. Gross O, Gewies A, Finger K, Schafer M, Spar-
wasser T, Peschel C, F€orster I, Ruland J. Card9
controls a non-TLR signalling pathway for innate
anti-fungal immunity. Nature 2006; 442:651-6;
PMID:16862125; http://dx.doi.org/10.1038/
nature04926
23. Bishu S, Hernandez-Santos N, Simpson-Abelson MR,
Huppler AR, Conti HR, Ghilardi N, Mamo AJ, Gaf-
fen SL. The adaptor CARD9 is required for adaptive
but not innate immunity to oral mucosal Candida
albicans infections. Infect Immun 2014; 82:1173-80;
PMID:24379290; http://dx.doi.org/10.1128/
IAI.01335-13
24. Gringhuis SI, den Dunnen J, Litjens M, van der Vlist
M, Wevers B, Bruijns SC, Geijtenbeek TB. Dectin-1
directs T helper cell differentiation by controlling
noncanonical NF-kappaB activation through Raf-1
and Syk. Nat Immunol 2009; 10:203-13;
PMID:19122653; http://dx.doi.org/10.1038/ni.1692
25. Robinson MJ, Osorio F, Rosas M, Freitas RP,
Schweighoffer E, Gross O, Verbeek JS, Ruland J,
Tybulewicz V, Brown GD, et al. Dectin-2 is a Syk-
coupled pattern recognition receptor crucial for Th17
responses to fungal infection. J Exp Med 2009;
206:2037-51; PMID:19703985; http://dx.doi.org/
10.1084/jem.20082818
26. Sato K, Yang XL, Yudate T, Chung JS, Wu J, Luby-
Phelps K, Kimberly RP, Underhill D, Cruz PD Jr,
Ariizumi K. Dectin-2 is a pattern recognition receptor
for fungi that couples with the Fc receptor gamma
chain to induce innate immune responses. J Biol
Chem 2006; 281:38854-66; PMID:17050534;
http://dx.doi.org/10.1074/jbc.M606542200
27. Beno DW, Stover AG, Mathews HL. Growth
inhibition of Candida albicans hyphae by CD8C
lymphocytes. J Immunol 1995; 154:5273-81;
PMID:7730631
28. de Repentigny L, Lewandowski D, Jolicoeur P.
Immunopathogenesis of oropharyngeal candidiasis in
human immunodeficiency virus infection. Clin
Microbiol Rev 2004; 17:729-59, table of contents;
PMID:15489345; http://dx.doi.org/10.1128/CMR.
17.4.729-759.2004
29. Fidel PL, Jr. Candida-host interactions in HIV dis-
ease: implications for oropharyngeal candidiasis. Adv
Dental Res 2011; 23:45-9; PMID:21441480; http://
dx.doi.org/10.1177/0022034511399284
30. Smeltz RB, Chen J, Ehrhardt R, Shevach EM. Role of
IFN-gamma in Th1 differentiation: IFN-gamma
334 Volume 6 Issue 4Virulence
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 01
:37
 22
 Ja
nu
ary
 20
16
 
regulates IL-18R alpha expression by preventing the
negative effects of IL-4 and by inducing/maintaining
IL-12 receptor beta 2 expression. J Immunol 2002;
168:6165-72; PMID:12055229; http://dx.doi.org/
10.4049/jimmunol.168.12.6165
31. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay
D, Gattorno M, Lanzavecchia A, Sallusto F, Napoli-
tani G. Surface phenotype and antigenic specificity of
human interleukin 17-producing T helper memory
cells. Nat Immunol 2007; 8:639-46;
PMID:17486092; http://dx.doi.org/10.1038/ni1467
32. Harrington LE, Hatton RD, Mangan PR, Turner H,
Murphy TL, Murphy KM, Weaver CT. Interleukin
17-producing CD4C effector T cells develop via a
lineage distinct from the T helper type 1 and 2 line-
ages. Nat Immunol 2005; 6:1123-32;
PMID:16200070; http://dx.doi.org/10.1038/ni1254
33. Kagami S, Rizzo HL, Kurtz SE, Miller LS, Blauvelt A.
IL-23 and IL-17A, but not IL-12 and IL-22, are
required for optimal skin host defense against Can-
dida albicans. J Immunol 2010; 185:5453-62;
PMID:20921529; http://dx.doi.org/10.4049/
jimmunol.1001153
34. Hernandez-Santos N, Huppler AR, Peterson AC,
Khader SA, McKenna KC, Gaffen SL. Th17 cells con-
fer long-term adaptive immunity to oral mucosal Can-
dida albicans infections. Mucosal Immunol 2013;
6:900-10; PMID:23250275; http://dx.doi.org/
10.1038/mi.2012.128
35. Yano J, Lilly E, Barousse M, Fidel PL, Jr. Epithelial
cell-derived S100 calcium-binding proteins as key
mediators in the hallmark acute neutrophil response
during Candida vaginitis. Infect Immun 2010;
78:5126-37; PMID:20823201; http://dx.doi.org/
10.1128/IAI.00388-10
36. Huang W, Na L, Fidel PL, Schwarzenberger P.
Requirement of interleukin-17A for systemic anti-
Candida albicans host defense in mice. J Infect Dis
2004; 190:624-31; PMID:15243941; http://dx.doi.
org/10.1086/422329
37. De Luca A, Zelante T, D’Angelo C, Zagarella S, Fal-
larino F, Spreca A, Iannitti RG, Bonifazi P, Renauld
JC, Bistoni F, et al. IL-22 defines a novel immune
pathway of antifungal resistance. Mucosal Immunol
2010; 3:361-73; PMID:20445503; http://dx.doi.org/
10.1038/mi.2010.22
38. Chung Y, Chang SH, Martinez GJ, Yang XO, Nur-
ieva R, Kang HS, Ma L, Watowich SS, Jetten AM,
Tian Q, et al. Critical regulation of early Th17 cell
differentiation by interleukin-1 signaling. Immunity
2009; 30:576-87; PMID:19362022; http://dx.doi.
org/10.1016/j.immuni.2009.02.007
39. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D,
Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A,
Sallusto F. Pathogen-induced human TH17 cells pro-
duce IFN-gamma or IL-10 and are regulated by IL-
1beta. Nature 2012; 484:514-8; PMID:22466287;
http://dx.doi.org/10.1038/nature10957
40. McGeachy MJ, Chen Y, Tato CM, Laurence A,
Joyce-Shaikh B, Blumenschein WM, McClanahan
TK, O’Shea JJ, Cua DJ. The interleukin 23 receptor
is essential for the terminal differentiation of interleu-
kin 17-producing effector T helper cells in vivo. Nat
Immunol 2009; 10:314-24; PMID:19182808; http://
dx.doi.org/10.1038/ni.1698
41. Moyes DL, Runglall M, Murciano C, Shen C, Nayar
D, Thavaraj S, Kohli A, Islam A, Mora-Montes H,
Challacombe SJ, et al. A biphasic innate immune
MAPK response discriminates between the yeast and
hyphal forms of Candida albicans in epithelial cells.
Cell Host Microbe 2010; 8:225-35;
PMID:20833374; http://dx.doi.org/10.1016/j.
chom.2010.08.002
42. Smeekens SP, van de Veerdonk FL, van der Meer JW,
Kullberg BJ, Joosten LA, Netea MG. The Candida
Th17 response is dependent on mannan- and beta-
glucan-induced prostaglandin E2. Int Immunol 2010;
22:889-95; PMID:21059767; http://dx.doi.org/
10.1093/intimm/dxq442
43. Marks BR, Nowyhed HN, Choi JY, Poholek AC,
Odegard JM, Flavell RA, Craft J. Thymic self-reactiv-
ity selects natural interleukin 17-producing T cells
that can regulate peripheral inflammation. Nat Immu-
nol 2009; 10:1125-32; PMID:19734905; http://dx.
doi.org/10.1038/ni.1783
44. Tanaka S, Yoshimoto T, Naka T, Nakae S, Iwakura Y,
Cua D, Kubo M. Natural occurring IL-17 producing
T cells regulate the initial phase of neutrophil medi-
ated airway responses. J Immunol 2009; 183:7523-
30; PMID:19890042; http://dx.doi.org/10.4049/
jimmunol.0803828
45. Conti HR, Peterson AC, Brane L, Huppler AR, Her-
nandez-Santos N, Whibley N, Garg AV, Simpson-
Abelson MR, Gibson GA, Mamo AJ, et al. Oral-resi-
dent natural Th17 cells and gammadelta T cells con-
trol opportunistic Candida albicans infections. J Exp
Med 2014; PMID:25200028
46. Farah CS, Hu Y, Riminton S, Ashman RB. Distinct
roles for interleukin-12p40 and tumour necrosis fac-
tor in resistance to oral candidiasis defined by gene-
targeting. Oral Microbiol Immunol 2006; 21:252-5;
PMID:16842510; http://dx.doi.org/10.1111/j.1399-
302X.2006.00288.x
47. Conti HR, Shen F, Nayyar N, Stocum E, Sun JN,
Lindemann MJ, Ho AW, Hai JH, Yu JJ, Jung
JW, et al. Th17 cells and IL-17 receptor signaling
are essential for mucosal host defense against oral
candidiasis. J Exp Med 2009; 206:299-311;
PMID:19204111; http://dx.doi.org/10.1084/jem.
20081463
48. Ho AW, Shen F, Conti HR, Patel N, Childs EE,
Peterson AC, Hernandez-Santos N, Kolls JK, Kane
LP, Ouyang W, et al. IL-17RC is required for
immune signaling via an extended SEF/IL-17R signal-
ing domain in the cytoplasmic tail. J Immunol 2010;
185:1063-70; PMID:20554964; http://dx.doi.org/
10.4049/jimmunol.0903739
49. Ouederni M, Sanal O, Ikinciogullari A, Tezcan I,
Dogu F, Sologuren I, Pedraza-Sanchez S, Keser M,
Tanir G, Nieuwhof C, et al. Clinical features of Can-
didiasis in patients with inherited interleukin 12
receptor beta1 deficiency. Clin Infect Dis 2014;
58:204-13; PMID:24186907; http://dx.doi.org/
10.1093/cid/cit722
50. de Beaucoudrey L, Samarina A, Bustamante J, Cobat
A, Boisson-Dupuis S, Feinberg J, Al-Muhsen S,
Janniere L, Rose Y, de Suremain M, et al. Revisiting
human IL-12Rbeta1 deficiency: a survey of 141
patients from 30 countries. Medicine (Baltimore)
2010; 89:381-402; PMID:21057261; http://dx.doi.
org/10.1097/MD.0b013e3181fdd832
51. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A,
Ghandil P, Chrabieh M, Feinberg J, von Bernuth H,
Samarina A, Janniere L, et al. Mutations in STAT3
and IL12RB1 impair the development of human IL-
17-producing T cells. J Exp Med 2008; 205:1543-50;
PMID:18591412; http://dx.doi.org/10.1084/jem.
20080321
52. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong
M, Grimbacher B, Fulcher DA, Tangye SG, Cook
MC. Deficiency of Th17 cells in hyper IgE syndrome
due to mutations in STAT3. J Exp Med 2008;
205:1551-7; PMID:18591410; http://dx.doi.org/
10.1084/jem.20080218
53. Renner ED, Rylaarsdam S, Anover-Sombke S, Rack
AL, Reichenbach J, Carey JC, Zhu Q, Jansson AF,
Barboza J, Schimke LF, et al. Novel signal transducer
and activator of transcription 3 (STAT3) mutations,
reduced T(H)17 cell numbers, and variably defective
STAT3 phosphorylation in hyper-IgE syndrome. J
Allergy Clin Immunol 2008; 122:181-7;
PMID:18602572; http://dx.doi.org/10.1016/j.
jaci.2008.04.037
54. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H,
Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O,
et al. Dominant-negative mutations in the DNA-
binding domain of STAT3 cause hyper-IgE syn-
drome. Nature 2007; 448:1058-62; PMID:
17676033; http://dx.doi.org/10.1038/nature06096
55. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP,
Uzel G, Brodsky N, Freeman AF, Demidowich A,
Davis J, Turner ML, et al. STAT3 mutations in
the hyper-IgE syndrome. N Engl J Med 2007;
357:1608-19; PMID:17881745; http://dx.doi.org/
10.1056/NEJMoa073687
56. Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S,
Abhyankar A, Toubiana J, Itan Y, Audry M, Nitschke
P, et al. Gain-of-function human STAT1 mutations
impair IL-17 immunity and underlie chronic mucocu-
taneous candidiasis. J Exp Med 2011; 208:1635-48;
PMID:21727188; http://dx.doi.org/10.1084/jem.
20110958
57. Glocker EO, Hennigs A, Nabavi M, Schaffer AA,
Woellner C, Salzer U, Pfeifer D, Veelken H, Warnatz
K, Tahami F, et al. A homozygous CARD9 mutation
in a family with susceptibility to fungal infections. N
Engl J Med 2009; 361:1727-35; PMID:19864672;
http://dx.doi.org/10.1056/NEJMoa0810719
58. Drewniak A, Gazendam RP, Tool AT, van Houdt M,
Jansen MH, van Hamme JL, van Leeuwen EM, Roos
D, Scalais E, de Beaufort C, et al. Invasive fungal
infection and impaired neutrophil killing in human
CARD9 deficiency. Blood 2013; 121:2385-92;
PMID:23335372; http://dx.doi.org/10.1182/blood-
2012-08-450551
59. Aaltonen J, Horelli-Kuitunen N, Fan JB, Bjorses P,
Perheentupa J, Myers R, Palotie A, Peltonen L. High-
resolution physical and transcriptional mapping of the
autoimmune polyendocrinopathy-candidiasis-ectoder-
mal dystrophy locus on chromosome 21q22.3 by
FISH. Genome Res 1997; 7:820-9; PMID:9267805
60. Nagamine K, Peterson P, Scott HS, Kudoh J, Min-
oshima S, Heino M, Krohn KJ, Lalioti MD, Mullis
PE, Antonarakis SE, et al. Positional cloning of the
APECED gene. Nat Genet 1997; 17:393-8;
PMID:9398839; http://dx.doi.org/10.1038/ng1297-
393
61. Puel A, Doffinger R, Natividad A, Chrabieh M,
Barcenas-Morales G, Picard C, Cobat A, Ouachee-
Chardin M, Toulon A, Bustamante J, et al. Autoanti-
bodies against IL-17A, IL-17F, and IL-22 in patients
with chronic mucocutaneous candidiasis and autoim-
mune polyendocrine syndrome type I. J Exp Med
2010; 207:291-7; PMID:20123958; http://dx.doi.
org/10.1084/jem.20091983
62. Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel
L, Link M, Kisand KV, Ersvaer E, Perheentupa J,
Erichsen MM, Bratanic N, et al. Chronic mucocu-
taneous candidiasis in APECED or thymoma
patients correlates with autoimmunity to Th17-
associated cytokines. J Exp Med 2010; 207:299-
308; PMID:20123959; http://dx.doi.org/10.1084/
jem.20091669
63. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L,
Lim HK, Migaud M, Israel L, Chrabieh M, Audry M,
et al. Chronic mucocutaneous candidiasis in humans
with inborn errors of interleukin-17 immunity. Sci-
ence 2011; 332:65-8; PMID:21350122; http://dx.
doi.org/10.1126/science.1200439
64. Boisson B, Wang C, Pedergnana V, Wu L, Cypowyj
S, Rybojad M, Belkadi A, Picard C, Abel L, Fieschi C,
et al. An ACT1 mutation selectively abolishes inter-
leukin-17 responses in humans with chronic mucocu-
taneous candidiasis. Immunity 2013; 39:676-86;
PMID:24120361; http://dx.doi.org/10.1016/j.
immuni.2013.09.002
65. Chaffin WL. Candida albicans cell wall proteins.
Microbiol Mol Biol Rev 2008; 72:495-544;
PMID:18772287; http://dx.doi.org/10.1128/
MMBR.00032-07
www.tandfonline.com 335Virulence
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 01
:37
 22
 Ja
nu
ary
 20
16
 
66. Moragues MD, Omaetxebarria MJ, Elguezabal N,
Sevilla MJ, Conti S, Polonelli L, Ponton J. A mono-
clonal antibody directed against a Candida albicans
cell wall mannoprotein exerts three anti-C. albicans
activities. Infect Immun 2003; 71:5273-9;
PMID:12933874; http://dx.doi.org/10.1128/
IAI.71.9.5273-5279.2003
67. Viudes A, Lazzell A, Perea S, Kirkpatrick WR, Peman
J, Patterson TF, Martinez JP, Lopez-Ribot JL. The C-
terminal antibody binding domain of Candida albi-
cans mp58 represents a protective epitope during can-
didiasis. FEMS Microbiol Lett 2004; 232:133-8;
PMID:15033231; http://dx.doi.org/10.1016/S0378-
1097(04)00042-4
68. Han Y, Morrison RP, Cutler JE. A vaccine and mono-
clonal antibodies that enhance mouse resistance to
Candida albicans vaginal infection. Infect Immun
1998; 66:5771-6; PMID:9826353
69. Han Y, Cutler JE. Antibody response that protects
against disseminated candidiasis. Infect Immun 1995;
63:2714-9; PMID:7790089
70. Zhang MX, Bohlman MC, Itatani C, Burton DR,
Parren PW, St Jeor SC, Kozel TR. Human recom-
binant antimannan immunoglobulin G1 antibody
confers resistance to hematogenously disseminated
candidiasis in mice. Infect Immun 2006; 74:362-
9; PMID:16368991; http://dx.doi.org/10.1128/
IAI.74.1.362-369.2006
71. Brena S, Omaetxebarria MJ, Elguezabal N, Cabezas J,
Moragues MD, Ponton J. Fungicidal monoclonal
antibody C7 binds to Candida albicans Als3. Infect
Immun 2007; 75:3680-2; PMID:17452471; http://
dx.doi.org/10.1128/IAI.01840-06
72. Brena S, Cabezas-Olcoz J, Moragues MD, Fernan-
dez de Larrinoa I, Dominguez A, Quindos G,
Ponton J. Fungicidal monoclonal antibody C7
interferes with iron acquisition in Candida albi-
cans. Antimicrob Agents Chemother 2011;
55:3156-63; PMID:21518848; http://dx.doi.org/
10.1128/AAC.00892-10
73. De Bernardis F, Boccanera M, Adriani D, Spre-
ghini E, Santoni G, Cassone A. Protective role of
antimannan and anti-aspartyl proteinase antibodies
in an experimental model of Candida albicans vag-
initis in rats. Infect Immun 1997; 65:3399-405;
PMID:9234804
74. Matthews RC, Burnie JP, Howat D, Rowland T,
Walton F. Autoantibody to heat-shock protein 90 can
mediate protection against systemic candidosis.
Immunology 1991; 74:20-4; PMID:1718852
75. Carrow EW, Hector RF, Domer JE. Immunodeficient
CBA/N mice respond effectively to Candida albicans.
Clin Immunol Immunopathol 1984; 33:371-80;
PMID:6388927; http://dx.doi.org/10.1016/0090-
1229(84)90308-8
76. Jensen J, Warner T, Balish E. Resistance of SCID
mice to Candida albicans administered intravenously
or colonizing the gut: role of polymorphonuclear leu-
kocytes and macrophages. J Infect Dis 1993;
167:912-9; PMID:8383723; http://dx.doi.org/
10.1093/infdis/167.4.912
77. Jensen J, Warner T, Balish E. The role of phagocytic
cells in resistance to disseminated candidiasis in granu-
locytopenic mice. J Infect Dis 1994; 170:900-5;
PMID:7930734; http://dx.doi.org/10.1093/infdis/
170.4.900
78. Torosantucci A, Romagnoli G, Chiani P, Stringaro A,
Crateri P, Mariotti S, Teloni R, Arancia G, Cassone
A, Nisini R. Candida albicans yeast and germ tube
forms interfere differently with human monocyte dif-
ferentiation into dendritic cells: a novel dimorphism-
dependent mechanism to escape the host’s immune
response. Infect Immun 2004; 72:833-43;
PMID:14742527; http://dx.doi.org/10.1128/
IAI.72.2.833-843.2004
79. d’Ostiani CF, Del Sero G, Bacci A, Montagnoli C,
Spreca A, Mencacci A, Ricciardi-Castagnoli P,
Romani L. Dendritic cells discriminate between yeasts
and hyphae of the fungus Candida albicans. Implica-
tions for initiation of T helper cell immunity in vitro
and in vivo. J Exp Med 2000; 191:1661-74;
PMID:10811860; http://dx.doi.org/10.1084/
jem.191.10.1661
80. Bacci A, Montagnoli C, Perruccio K, Bozza S, Gaz-
iano R, Pitzurra L, Velardi A, d’Ostiani CF, Cutler
JE, Romani L. Dendritic cells pulsed with fungal
RNA induce protective immunity to Candida albicans
in hematopoietic transplantation. J Immunol 2002;
168:2904-13; PMID:11884461; http://dx.doi.org/
10.4049/jimmunol.168.6.2904
81. Cheng SC, van de Veerdonk F, Smeekens S, Joosten
LA, van der Meer JW, Kullberg BJ, Netea MG. Can-
dida albicans dampens host defense by downregulat-
ing IL-17 production. J Immunol 2010; 185:2450-7;
PMID:20624941; http://dx.doi.org/10.4049/
jimmunol.1000756
82. Zelante T, Iannitti RG, De Luca A, Arroyo J, Blanco
N, Servillo G, Sanglard D, Reichard U, Palmer GE,
Latge JP, et al. Sensing of mammalian IL-17A regu-
lates fungal adaptation and virulence. Nat Commun
2012; 3:683; PMID:22353714; http://dx.doi.org/
10.1038/ncomms1685
83. Whibley N, Maccallum DM, Vickers MA, Zafreen S,
Waldmann H, Hori S, Gaffen SL, Gow NA, Barker
RN, Hall AM. Expansion of Foxp3(C) T-cell popula-
tions by Candida albicans enhances both Th17-cell
responses and fungal dissemination after intravenous
challenge. Eur J Immunol 2014; 44:1069-83;
PMID:24435677; http://dx.doi.org/10.1002/
eji.201343604
84. Pandiyan P, Conti HR, Zheng L, Peterson AC, Math-
ern DR, Hernandez-Santos N, Edgerton M, Gaffen
SL, Lenardo MJ. CD4(C)CD25(C)Foxp3(C) regula-
tory T cells promote Th17 cells in vitro and enhance
host resistance in mouse Candida albicans Th17 cell
infection model. Immunity 2011; 34:422-34;
PMID:21435589; http://dx.doi.org/10.1016/j.
immuni.2011.03.002
85. Lamkanfi M, Dixit Vishva M. Mechanisms and Func-
tions of Inflammasomes. Cell 2014; 157:1013-22;
PMID:24855941; http://dx.doi.org/10.1016/j.
cell.2014.04.007
86. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lav-
elle EC, Mills KH. Interleukin-1 and IL-23 induce
innate IL-17 production from gammadelta T cells,
amplifying Th17 responses and autoimmunity.
Immunity 2009; 31:331-41; PMID:19682929;
http://dx.doi.org/10.1016/j.immuni.2009.08.001
87. Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher
JM, Mills KH. Caspase-1-processed cytokines IL-
1beta and IL-18 promote IL-17 production by gam-
madelta and CD4 T cells that mediate autoimmunity.
J Immunol 2011; 186:5738-48; PMID:21471445;
http://dx.doi.org/10.4049/jimmunol.1003597
88. Joly S, Ma N, Sadler JJ, Soll DR, Cassel SL, Sutter-
wala FS. Cutting edge: Candida albicans hyphae for-
mation triggers activation of the Nlrp3
inflammasome. J Immunol 2009; 183:3578-81;
PMID:19684085; http://dx.doi.org/10.4049/
jimmunol.0901323
89. Hise AG, Tomalka J, Ganesan S, Patel K, Hall BA,
Brown GD, Fitzgerald KA. An essential role for the
NLRP3 inflammasome in host defense against the
human fungal pathogen Candida albicans. Cell Host
Microbe 2009; 5:487-97; PMID:19454352; http://
dx.doi.org/10.1016/j.chom.2009.05.002
90. Gross O, Poeck H, Bscheider M, Dostert C, Han-
nesschlager N, Endres S, Hartmann G, Tardivel A,
Schweighoffer E, Tybulewicz V, et al. Syk kinase sig-
nalling couples to the Nlrp3 inflammasome for anti-
fungal host defence. Nature 2009; 459:433-6;
PMID:19339971; http://dx.doi.org/10.1038/
nature07965
91. Kumar H, Kumagai Y, Tsuchida T, Koenig PA, Satoh
T, Guo Z, Jang MH, Saitoh T, Akira S, Kawai T.
Involvement of the NLRP3 inflammasome in innate
and humoral adaptive immune responses to fungal
beta-glucan. J Immunol 2009; 183:8061-7;
PMID:20007575; http://dx.doi.org/10.4049/
jimmunol.0902477
92. van de Veerdonk FL, Joosten LA, Shaw PJ, Smeekens
SP, Malireddi RK, van der Meer JW, Kullberg BJ,
Netea MG, Kanneganti TD. The inflammasome
drives protective Th1 and Th17 cellular responses in
disseminated candidiasis. Eur J Immunol 2011;
41:2260-8; PMID:21681738; http://dx.doi.org/
10.1002/eji.201041226
93. Tomalka J, Ganesan S, Azodi E, Patel K, Majmudar
P, Hall BA, Fitzgerald KA, Hise AG. A novel role for
the NLRC4 inflammasome in mucosal defenses
against the fungal pathogen Candida albicans. PLoS
Pathog 2011; 7:e1002379
94. Joly S, Eisenbarth SC, Olivier AK, Williams A,
Kaplan DH, Cassel SL, Flavell RA, Sutterwala FS.
Cutting edge: Nlrp10 is essential for protective anti-
fungal adaptive immunity against Candida albicans. J
Immunol 2012; 189:4713-7; PMID:23071280;
http://dx.doi.org/10.4049/jimmunol.1201715
95. Gringhuis SI, Kaptein TM, Wevers BA, Theelen B,
van der Vlist M, Boekhout T, Geijtenbeek TB. Dec-
tin-1 is an extracellular pathogen sensor for the induc-
tion and processing of IL-1beta via a noncanonical
caspase-8 inflammasome. Nat Immunol 2012;
13:246-54; PMID:22267217; http://dx.doi.org/
10.1038/ni.2222
96. Sobel JD. Pathogenesis and epidemiology of vulvova-
ginal candidiasis. Ann N Y Acad Sci 1988; 544:547-
57; PMID:3063184; http://dx.doi.org/10.1111/
j.1749-6632.1988.tb40450.x
97. Sobel JD. Pathogenesis and treatment of recurrent
vulvovaginal candidiasis. Clin Infect Dis 1992; 14
Suppl 1:S148-53; PMID:1562688; http://dx.doi.org/
10.1093/clinids/14.Supplement_1.S148
98. Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J.
Prevalence of recurrent vulvovaginal candidiasis in 5
European countries and the United States: results
from an internet panel survey. J Lower Genital Tract
Dis 2013; 17:340-5; PMID:23486072; http://dx.doi.
org/10.1097/LGT.0b013e318273e8cf
99. Fidel PL, Jr. Immunity in vaginal candidiasis. Curr
Opin Infect Dis 2005; 18:107-11; PMID:15735412;
http://dx.doi.org/10.1097/01.qco.0000160897.
74492.a3
100. Yano J, Kolls JK, Happel KI, Wormley F, Wozniak
KL, Fidel PL, Jr. The acute neutrophil response medi-
ated by S100 alarmins during vaginal Candida infec-
tions is independent of the Th17-pathway. PLoS One
2012; 7:e46311
101. Cenci E, Mencacci A, Spaccapelo R, Tonnetti L,
Mosci P, Enssle KH, Puccetti P, Romani L, Bistoni F.
T helper cell type 1 (Th1)- and Th2-like responses are
present in mice with gastric candidiasis but protective
immunity is associated with Th1 development. J
Infect Dis 1995; 171:1279-88; PMID:7751704;
http://dx.doi.org/10.1093/infdis/171.5.1279
102. Romani L, Mencacci A, Cenci E, Spaccapelo R, Mosci
P, Puccetti P, Bistoni F. CD4C subset expression in
murine candidiasis. Th responses correlate directly
with genetically determined susceptibility or vaccine-
induced resistance. J Immunol 1993; 150:925-31;
PMID:8093707
103. Romani L, Mocci S, Bietta C, Lanfaloni L, Puccetti P,
Bistoni F. Th1 and Th2 cytokine secretion patterns in
murine candidiasis: association of Th1 responses with
acquired resistance. Infect Immun 1991; 59:4647-54;
PMID:1682265
104. Fidel PL, Jr. History and update on host defense
against vaginal candidiasis. Am J Reproduct Immunol
2007; 57:2-12; PMID:17156186; http://dx.doi.org/
10.1111/j.1600-0897.2006.00450.x
105. LeBlanc DM, Barousse MM, Fidel PL, Jr. Role for
dendritic cells in immunoregulation during experi-
mental vaginal candidiasis. Infect Immun 2006;
336 Volume 6 Issue 4Virulence
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 01
:37
 22
 Ja
nu
ary
 20
16
 
74:3213-21; PMID:16714548; http://dx.doi.org/
10.1128/IAI.01824-05
106. Oriss TB, Ostroukhova M, Seguin-Devaux C, Dixon-
McCarthy B, Stolz DB, Watkins SC, Pillemer B, Ray
P, Ray A. Dynamics of dendritic cell phenotype and
interactions with CD4C T cells in airway inflamma-
tion and tolerance. J Immunol 2005; 174:854-63;
PMID:15634907; http://dx.doi.org/10.4049/
jimmunol.174.2.854
107. Pietrella D, Rachini A, Pines M, Pandey N, Mosci P,
Bistoni F, d’Enfert C, Vecchiarelli A. Th17 cells and
IL-17 in protective immunity to vaginal candidiasis.
PLoS One 2011; 6:e22770; PMID:21818387; http://
dx.doi.org/10.1371/journal.pone.0022770
108. Yano J, Palmer GE, Eberle KE, Peters BM, Vogl T,
McKenzie AN, Fidel PL Jr. Vaginal epithelial cell-
derived S100 alarmins induced by Candida albicans
via pattern recognition receptor interactions are suffi-
cient but not necessary for the acute neutrophil
response during experimental vaginal candidiasis.
Infect Immun 2014; 82:783-92; PMID:24478092;
http://dx.doi.org/10.1128/IAI.00861-13
109. Fidel PL, Jr., Barousse M, Espinosa T, Ficarra M,
Sturtevant J, Martin DH, Quayle AJ, Dunlap K. An
intravaginal live Candida challenge in humans leads
to new hypotheses for the immunopathogenesis of
vulvovaginal candidiasis. Infect Immun 2004;
72:2939-46; PMID:15102806; http://dx.doi.org/
10.1128/IAI.72.5.2939-2946.2004
110. Hoyer LL, Green CB, Oh SH, Zhao X. Discovering
the secrets of the Candida albicans agglutinin-like
sequence (ALS) gene family–a sticky pursuit. Med
Mycol 2008; 46:1-15; PMID:17852717; http://dx.
doi.org/10.1080/13693780701435317
111. de Groot PW, Bader O, de Boer AD, Weig M,
Chauhan N. Adhesins in human fungal pathogens:
glue with plenty of stick. Eukaryot Cell 2013;
12:470-81; PMID:23397570; http://dx.doi.org/
10.1128/EC.00364-12
112. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V,
Baquir B, Fu Y, French SW, Edwards JE, Jr, Spellberg
B, et al. Th1-Th17 cells mediate protective adaptive
immunity against Staphylococcus aureus and Candida
albicans infection in mice. PLoS Pathog 2009; 5:
e1000703
113. Ibrahim AS, Luo G, Gebremariam T, Lee H, Schmidt
CS, Hennessey JP, Jr., French SW, Yeaman MR,
Filler SG, Edwards JE Jr. NDV-3 protects mice from
vulvovaginal candidiasis through T- and B-cell
immune response. Vaccine 2013; 31:5549-56;
PMID:24063977; http://dx.doi.org/10.1016/j.
vaccine.2013.09.016
114. Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers
C, Phan QT, Filler SG, Yeaman MR, Edwards JE Jr.
Efficacy of the anti-Candida rAls3p-N or rAls1p-N
vaccines against disseminated and mucosal candidia-
sis. J Infect Dis 2006; 194:256-60; PMID:16779733;
http://dx.doi.org/10.1086/504691
115. Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y,
Yeaman MR, Edwards JE Jr, Hennessey JP Jr. NDV-
3, a recombinant alum-adjuvanted vaccine for Can-
dida and Staphylococcus aureus, is safe and immuno-
genic in healthy adults. Vaccine 2012; 30:7594-600;
PMID:23099329; http://dx.doi.org/10.1016/j.
vaccine.2012.10.038
116. Ibrahim AS, Spellberg BJ, Avenissian V, Fu Y, Filler
SG, Edwards JE, Jr. Vaccination with recombinant
N-terminal domain of Als1p improves survival during
murine disseminated candidiasis by enhancing cell-
mediated, not humoral, immunity. Infect Immun
2005; 73:999-1005; PMID:15664943; http://dx.doi.
org/10.1128/IAI.73.2.999-1005.2005
117. Spellberg BJ, Ibrahim AS, Avenissian V, Filler SG,
Myers CL, Fu Y, Edwards JE Jr. The anti-Candida
albicans vaccine composed of the recombinant N ter-
minus of Als1p reduces fungal burden and improves
survival in both immunocompetent and immunocom-
promised mice. Infect Immun 2005; 73:6191-3;
PMID:16113347; http://dx.doi.org/10.1128/
IAI.73.9.6191-6193.2005
118. Ibrahim AS, Spellberg BJ, Avanesian V, Fu Y,
Edwards JE, Jr. The anti-Candida vaccine based on
the recombinant N-terminal domain of Als1p is
broadly active against disseminated candidiasis. Infect
Immun 2006; 74:3039-41; PMID:16622247; http://
dx.doi.org/10.1128/IAI.74.5.3039-3041.2006
119. Bar E, Gladiator A, Bastidas S, Roschitzki B, Acha-
Orbea H, Oxenius A, LeibundGut-Landmann S. A
novel Th cell epitope of Candida albicans mediates
protection from fungal infection. J Immunol 2012;
188:5636-43; PMID:22529294; http://dx.doi.org/
10.4049/jimmunol.1200594
120. Naglik JR, Challacombe SJ, Hube B. Candida albi-
cans secreted aspartyl proteinases in virulence and
pathogenesis. Microbiol Mol Biol Rev 2003; 67:400-
28, table of contents; PMID:12966142; http://dx.doi.
org/10.1128/MMBR.67.3.400-428.2003
121. Vilanova M, Teixeira L, Caramalho I, Torrado E,
Marques A, Madureira P, Ribeiro A, Ferreira P,
Gama M, Demengeot J. Protection against systemic
candidiasis in mice immunized with secreted aspartic
proteinase 2. Immunology 2004; 111:334-42;
PMID:15009435; http://dx.doi.org/10.1111/j.1365-
2567.2004.01819.x
122. Sandini S, La Valle R, Deaglio S, Malavasi F, Cas-
sone A, De Bernardis F. A highly immunogenic
recombinant and truncated protein of the secreted
aspartic proteases family (rSap2t) of Candida albi-
cans as a mucosal anticandidal vaccine. FEMS
Immunol Med Microbiol 2011; 62:215-24;
PMID:21535228; http://dx.doi.org/10.1111/
j.1574-695X.2011.00802.x
123. Torosantucci A, Bromuro C, Chiani P, De Bernardis
F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L,
Costantino P. A novel glyco-conjugate vaccine against
fungal pathogens. J Exp Med 2005; 202:597-606;
PMID:16147975; http://dx.doi.org/10.1084/
jem.20050749
www.tandfonline.com 337Virulence
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 01
:37
 22
 Ja
nu
ary
 20
16
 
